- Active not recruitingPHASE2
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
This study looks at new ways to treat a type of bladder cancer that hasn't responded to usual treatments. It tests two medicines, TAR-200 and cetrelimab, alone or together, for people who can't or don't want major surgery.
For: Urinary Bladder NeoplasmsUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
This study looks at new treatments for a type of bladder cancer that hasn't spread into the muscle. It compares new drugs, TAR-200 (alone or with Cetrelimab), against the usual treatment, BCG, to see which works best and is safest.
For: Bladder CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
This study compares a new treatment, TAR-200, with standard chemotherapy for a type of bladder cancer that has returned after initial treatment. It's for people who can't or won't have surgery to remove their bladder.
For: Non-Muscle Invasive Bladder NeoplasmsUnited States · Argentina · Belgium - Active not recruitingPHASE2
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
This study is testing new treatments for a type of bladder cancer called muscle-invasive urothelial carcinoma. Researchers are looking at TAR-200 with cetrelimab, and cetrelimab on its own, to see how well they work against the cancer.
For: Urinary Bladder NeoplasmsUnited States · Belgium · France